

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

May 2023

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a background of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 May 2023	3
Section H changes to Part II	4
Index	7

Summary of decisions

EFFECTIVE 1 MAY 2023

- Ambrisentan (Ambrisentan Viatris) tab 5 mg – new listing
- Atenolol (Mylan Atenolol) tab 50 mg – to be delisted 1 November 2023
- Bisoprolol fumarate (Bisoprolol Mylan) tab 2.5 mg and 5 mg – to be delisted 1 November 2023
- Emtricitabine with tenofovir disoproxil (Tenofovir Disoproxil Emtricitabine Mylan) tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – to be delisted 1 November 2023
- Lamivudine (Lamivudine Alphapharm) tab 150 mg – to be delisted 1 November 2023
- Lidocaine [lignocaine] hydrochloride with chlorhexidine (Pfizer) gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe – to be delisted 1 November 2023
- Lithium carbonate (Douglas) cap 250 mg – price increase
- Lopinavir with ritonavir (Kaletra) oral liq 80 mg with ritonavir 20 mg per ml, 300 ml – delisted 1 May 2023
- Macrogol 3350 with potassium chloride and sodium chloride with/without sodium sulfate, sodium ascorbate, ascorbic acid (Plenvu) powder for oral soln 100 g with potassium chloride 1 g, sodium chloride 2 g and sodium sulfate 9 g per sachet (1), powder for oral soln 40 g with potassium chloride 1.2 g and sodium chloride 3.2 g per sachet (1) and powder for oral soln ascorbic acid 7.54 g and sodium ascorbate 48.11 g per sachet (1) – new listing and addition of PSS
- Nepafenac eye drops 0.3% – new listing
- Nicotine (Habitrol) gum 2 mg (Fruit) and 4 mg (Mint) – new 204 piece pack size
- Oxaliplatin (Alchemy Oxaliplatin) inj 5 mg per ml, 20 ml vial – new listing and addition of PSS
- Oxaliplatin (Oxaliplatin Accord) inj 5 mg per ml, 20 ml vial – to be delisted 1 October 2023
- Risdiplam (Evrysdi) powder for oral soln 750 mcg per ml, 60 mg per bottle, 80 ml – new listing
- Tenofovir Disoproxil (Tenofovir Disoproxil Viatris) tab 245 mg (300 mg as a maleate) – new listing
- Vinorelbine (Vinorelbine Te Arai) cap 20 mg, 30 mg and 80 mg – new listing and addition of PSS
- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml vial – to be delisted 1 November 2023

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 May 2023

ALIMENTARY TRACT AND METABOLISM

14	MACROGOL 3350 WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE WITH/WITHOUT SODIUM SULFATE, SODIUM ASCORBATE, ASCORBIC ACID (new listing and addition of PSS) Powder for oral soln 100 g with potassium chloride 1 g, sodium chloride 2 g and sodium sulfate 9 g per sachet (1), powder for oral soln 40 g with potassium chloride 1.2 g and sodium chloride 3.2 g per sachet (1) and powder for oral soln ascorbic acid 7.54 g and sodium ascorbate 48.11 g per sachet (1) – 5% DV Oct-23 to 2026	18.52	3	Plenvu
----	---	-------	---	--------

CARDIOVASCULAR SYSTEM

46	ATENOLOL (delisting) Tab 50 mg – 5% DV Jan-22 to 2024	9.33	500	Mylan Atenolol
Note – Mylan Atenolol tab 50 mg to be delisted from 1 November 2023.				
46	BISOPROLOL FUMARATE (delisting) Tab 2.5 mg – 1% DV Apr-21 to 2023	1.84	90	Bisoprolol Mylan
	Tab 5 mg – 1% DV Apr-21 to 2023	2.55	90	Bisoprolol Mylan
Note – Bisoprolol Mylan tab 2.5 mg and 5 mg to be delisted from 1 November 2023.				
54	AMBRISENTAN (new listing) → Tab 5 mg.....	1,550.00	30	Ambrisentan Viatris

HORMONE PREPARATIONS

70	ZOLEDRONIC ACID (delisting) Inj 4 mg per 5 ml, vial – 5% DV Dec-21 to 2024	18.00	1	Zoledronic acid Mylan
Note – Zoledronic acid Mylan inj 4 mg per 5 ml, vial to be delisted from 1 November 2023.				

INFECTIONS

93	LAMIVUDINE (delisting) → Tab 150 mg – 1% DV Nov-20 to 2023.....	84.50	60	Lamivudine Alphapharm
Note – Lamivudine Alphapharm tab 150 mg to be delisted from 1 November 2023.				
95	LOPINAVIR WITH RITONAVIR (delisting) → Oral liq 80 mg with ritonavir 20 mg per ml.....	735.00	300 ml	Kaletra
Note: Kaletra oral liq 80mg with ritonavir 20 mg per ml delisted on 1 May 2023.				
96	TENOFOVIR DISOPROXIL (new listing) Tab 245 mg (300 mg as a maleate)	15.00	30	Tenofovir Disoproxil Viatris

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 May 2023 (continued)

97	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (delisting) → Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – 5% DV Dec-22 to 2025.....	15.45	30	Tenofovir Disoproxil Emtricitabine Mylan
----	---	-------	----	---

Note – Tenofovir Disoproxil Emtricitabine Mylan tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) to be delisted from 1 November 2023.

NERVOUS SYSTEM

112	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE with chlorhexidine (delisting) Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe	103.32	10	Pfizer
-----	--	--------	----	--------

Note – Pfizer gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes to be delisted from 1 November 2023.

124	LITHIUM CARBONATE († price) Cap 250 mg	22.36	100	Douglas
-----	---	-------	-----	---------

129	RISDIPLAM (new listing) Note: the supply of risdiplam is via Pharmac’s approved direct distribution supply. Further details can be found on Pharmac’s website https://pharmac.govt.nz/risdiplam → Powder for oral soln 750 mcg per ml, 60 mg per bottle.....	14,100.00	80 ml	Evrysdi
-----	---	-----------	-------	---------

Restricted
Initiation

Re-assessment required after 12 months

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
 - 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Continuation

Re-assessment required after 12 months

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

133	NICOTINE (new listing) Gum 2 mg	21.42	204	Habitrol (Fruit)
	Gum 4 mg	24.17	204	Habitrol (Mint)

Note: Change in pack size. New Pharmacode for 2 mg (2640589) and 4 mg (2640570).

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2023 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

145	OXALIPLATIN (new listing and addition of PSS) Inj 5 mg per ml, 20 ml vial – 5% DV Oct-23 to 2024	33.35	1	Alchemy Oxaliplatin
Note – Oxaliplatin Accord inj 5 mg per ml, 20 ml vial to be delisted from 1 October 2023.				
153	VINORELBINE (new listing and addition of PSS) Cap 20 mg – 5% DV Oct-23 to 2025	30.00	1	Vinorelbine Te Arai
	Cap 30 mg – 5% DV Oct-23 to 2025	40.00	1	Vinorelbine Te Arai
	Cap 80 mg – 5% DV Oct-23 to 2025	60.00	1	Vinorelbine Te Arai

SENSORY ORGANS

242	NEPAFENAC (new listing) Eye drops 0.3%			
-----	---	--	--	--

Index

Pharmaceuticals and brands

A

Alchemy Oxaliplatin 6

Ambrisentan 4

Ambrisentan Viatrix 4

Atenolol 4

B

Bisoprolol fumarate 4

Bisoprolol Mylan 4

E

Emtricitabine with tenofovir disoproxil 5

Evrysdi 5

H

Habitrol (Fruit) 5

Habitrol (Mint) 5

K

Kaletra 4

L

Lamivudine 4

Lamivudine Alphapharm 4

Lidocaine [Lignocaine] hydrochloride 5

Lignocaine 5

Lithium carbonate 5

Lopinavir with ritonavir 4

M

Macrogol 3350 with potassium chloride and sodium chloride with/without sodium sulfate, sodium ascorbate, ascorbic acid 4

Mylan Atenolol 4

N

Nepafenac 6

Nicotine 5

O

Oxaliplatin 6

P

Plenvu 4

R

Risdiplam 5

T

Tenofovir disoproxil 4

Tenofovir Disoproxil Emtricitabine Mylan 5

Tenofovir Disoproxil Viatrix 4

V

Vinorelbine 6

Vinorelbine Te Arai 6

Z

Zoledronic acid 4

Zoledronic acid Mylan 4

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

